List view / Grid view

Boehringer Ingelheim

 

news

OFEV® (nintedanib*) approved in the EU for the treatment of IPF

19 January 2015 | By Boehringer Ingelheim

Boehringer Ingelheim today announced that the European Commission (EC) has approved nintedanib* for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHMP opinion on 20 November 2014. Nintedanib* will be marketed in the EU under the brand name OFEV®...